Acute progression of recurrent meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer.
Acute progression of recurrent meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer.
复制标题
黄体生成素释放激素激动剂治疗前列腺癌期间复发性脑膜瘤的急性进展。
DOI：
10.1016/j.wneu.2016.03.076
复制
发表时间：
2016
影响因子：
2
通讯作者：
Nakada M
中科院分区：
文献类型：
--
作者：
Tsutsui T;Miyashita K;Sabit H;Fukui I;Hayashi Y;Mizokami A;Ikeda H;Nagatani H;Nakada M
背景：脑膜瘤是最常见的良性脑肿瘤，女性脑膜瘤的发病率是男性的两倍多。一些研究已经证明激素在某种程度上与脑膜瘤的生长有关。病例描述一位72岁男性良性脑膜瘤行肿瘤切除术，18年无复发。他被发现患有前列腺癌，并接受了黄体生成素释放激素（LHRH）激动剂的激素治疗。两年后，他出现了严重的认知功能障碍和步态障碍。钆增强脑磁共振成像显示复发性大肿块和梗阻性脑积水。分期切除并对残余肿瘤进行立体定向放射治疗。经内窥镜第三脑室造口术治疗梗阻性脑积水后，患者症状改善，残留肿瘤保持稳定。结论：这是首例LHRH激动剂促进已存在脑膜瘤生长的病例报告。我们建议有脑膜瘤病史的患者在接受LHRH激动剂治疗时应密切监测。
BackgroundMeningiomas are the most common type of benign brain tumor, and the incidence of meningioma in women is more than twofold higher than in men. Several studies have demonstrated that hormones are somehow related to the growth of meningiomas.Case DescriptionA 72-year-old man with benign meningioma underwent tumor resection and had no recurrence for 18 years. He was found to have prostate cancer, and he received hormonal therapy with a luteinizing hormone-releasing hormone (LHRH) agonist. Two years later, he developed severe cognitive dysfunction and gait disturbance. Gadolinium-enhanced brain magnetic resonance imaging revealed a large recurrent mass and obstructive hydrocephalus. Staged resection was performed and stereotactic radiation therapy was administered against the residual tumor. His symptoms improved after endoscopic third ventriculostomy for obstructive hydrocephalus and his residual tumor remains stable.ConclusionsThis is the first report of a case in which an LHRH agonist promoted the growth of a pre-existing meningioma. We suggest that patients with a history of meningioma who are receiving LHRH agonist treatment should be closely monitored.